Frost & Sullivan puts some flesh on the bones of the idea that nanotechnology can be a profitable tool in drug development.

EU technology policy is moving beyond the numbers game, and getting down to economic basics.

With global revenues of $110 billion last year, and an aging population, the nascent "neurotechnology" market appears poised for huge growth.

The UK government has created two new Enterprise Capital Funds (ECF) under its £40 million scheme to aid high tech businesses caught in the equity gap.

Researchers at four European universities are collaborating to develop software that will help encourage the take-up of so called pervasive computing.

The lack of funding from the private sector is still holding back the development of the European biotech sector vis a vis the US despite a similar number of companies in each.

The European Commission wants businesses to spend more on research and development - and to help encourage that, the agency is preparing a volley of government proposals for the Autumn.

Secure Access Solutions, a spin-off from the University of Warwick, has developed a new kind of magnifying lens to help the visually impaired type their pin codes into card readers in shops. It is seeking licensees and investors.

Open source software has broken the stranglehold of proprietary software vendors. Could the Biological Open Source initiative do the same in biotech?

Nanomedicine can be more than a case of adding a trendy label to traditional approaches to pharmaceuticals.